RetinalGenix Technologies Welcomes Dr. Taimour Langaee as Advisor for DNA GPS Pharmacogenetics Initiatives

Core Insights - RetinalGenix Technologies Inc. has appointed Dr. Taimour Langaee as a scientific advisor to enhance its DNA GPS Pharmacogenetics initiatives aimed at optimizing personalized treatment pathways for retinal and systemic diseases [1][5] - Dr. Langaee brings over 20 years of experience in pharmacogenomics and precision medicine, overseeing genotyping, sequencing data processing, and clinical genetic association studies [2][3] - The company aims to integrate advanced retinal imaging with pharmacogenetics and AI to identify early signs of chronic diseases, thereby improving overall health management and reducing long-term healthcare costs [6][7] Company Overview - RetinalGenix is focused on revolutionizing early disease detection and improving patient outcomes by combining genetic screening, advanced imaging, and therapeutic development [9] - The company's proprietary technologies include High-Resolution Retinal Imaging and DNA/RNA/GPS Pharmaco-Genetic Mapping™, which are designed to prevent blindness and detect physiological changes indicating future ocular and systemic diseases [9] Strategic Goals - The integration of Dr. Langaee's expertise is expected to accelerate the company's efforts in delivering personalized, data-driven solutions for retinal and systemic health [5] - RetinalGenix's approach includes remote monitoring and personalized risk assessments based on genetic profiles, which aims to maximize the effectiveness of preventive strategies [7][8]